IL144577A0 - Peptidyl heterocyclic ketones useful as tryptase inhibitors - Google Patents

Peptidyl heterocyclic ketones useful as tryptase inhibitors

Info

Publication number
IL144577A0
IL144577A0 IL14457700A IL14457700A IL144577A0 IL 144577 A0 IL144577 A0 IL 144577A0 IL 14457700 A IL14457700 A IL 14457700A IL 14457700 A IL14457700 A IL 14457700A IL 144577 A0 IL144577 A0 IL 144577A0
Authority
IL
Israel
Prior art keywords
tryptase inhibitors
heterocyclic ketones
ketones useful
peptidyl
peptidyl heterocyclic
Prior art date
Application number
IL14457700A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL144577A0 publication Critical patent/IL144577A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14457700A 1999-01-27 2000-01-13 Peptidyl heterocyclic ketones useful as tryptase inhibitors IL144577A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11760299P 1999-01-27 1999-01-27
PCT/US2000/000883 WO2000044733A1 (en) 1999-01-27 2000-01-13 Peptidyl heterocyclic ketones useful as tryptase inhibitors

Publications (1)

Publication Number Publication Date
IL144577A0 true IL144577A0 (en) 2002-05-23

Family

ID=22373811

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14457700A IL144577A0 (en) 1999-01-27 2000-01-13 Peptidyl heterocyclic ketones useful as tryptase inhibitors

Country Status (24)

Country Link
US (2) US6469036B1 (cs)
EP (1) EP1147097A1 (cs)
JP (1) JP2002535394A (cs)
KR (1) KR20010110422A (cs)
CN (1) CN1353701A (cs)
AR (1) AR022427A1 (cs)
AU (1) AU3208500A (cs)
BG (1) BG105762A (cs)
BR (1) BR0007778A (cs)
CA (1) CA2361479A1 (cs)
CZ (1) CZ20012722A3 (cs)
EA (1) EA200100815A1 (cs)
EE (1) EE200100391A (cs)
HK (1) HK1038561A1 (cs)
HR (1) HRP20010601A2 (cs)
HU (1) HUP0201295A3 (cs)
IL (1) IL144577A0 (cs)
NO (1) NO20013666L (cs)
SK (1) SK10742001A3 (cs)
TR (1) TR200102766T2 (cs)
TW (1) TWI229669B (cs)
WO (1) WO2000044733A1 (cs)
YU (1) YU61401A (cs)
ZA (1) ZA200106995B (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EP1268418B1 (en) * 2000-03-27 2006-06-14 Applied Research Systems ARS Holding N.V. Pharmaceutically active pyrrolidine derivatives as bax inhibitors
MXPA02009382A (es) * 2000-03-27 2003-01-28 Applied Research Systems Derivados de pirrolidina farmaceuticamente activos.
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6797461B2 (en) * 2000-10-27 2004-09-28 Promega Corporation Tryptase substrates and assay for tryptase activity using same
WO2002055073A1 (fr) * 2001-01-05 2002-07-18 Kyowa Kakko Kogyo Co., Ltd. Agents prophylactiques de l'arthrite
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
GB0103765D0 (en) 2001-02-15 2001-04-04 Affitech As Assay
US20060183664A1 (en) * 2001-12-13 2006-08-17 Toshiaki Takizawa Pharmaceutical composition for delayed hypersensitivity
AU2003237224A1 (en) * 2002-05-29 2003-12-19 Merck And Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
DE10249304B4 (de) * 2002-10-22 2006-09-28 Cytec Surface Specialties Germany Gmbh & Co. Kg Wäßrige Beschichtungsmittel
US7205384B2 (en) 2003-08-05 2007-04-17 Ortho-Mcneil Pharmaceutical Inc. Process for preparing peptidyl heterocyclic ketone derivatives
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
US20050209232A1 (en) * 2004-02-10 2005-09-22 Kent Barbay Pyridazinone ureas as antagonists of alpha4 integrins
AU2005277203A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
AU2007253819B2 (en) * 2006-05-23 2011-02-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
MX2008014838A (es) * 2006-05-23 2008-12-05 Irm Llc Metodos y composiciones como inhibidores de proteasa de activacion de canal.
EP2117541A1 (en) * 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
BRPI0807483A2 (pt) 2007-02-09 2014-05-13 Irm Llc Compostos e composições como inibidores de protease de ativação de canal
KR101131238B1 (ko) 2007-02-09 2012-03-30 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
ES2351323B1 (es) * 2009-06-26 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
US9365853B2 (en) 2011-06-02 2016-06-14 SOCPRA Sciences Sante et Humaines S.E.C. Matriptase inhibitors and uses thereof against orthomyxoviridae infections
CN103145598B (zh) * 2011-12-07 2014-10-15 北京京卫顺康医药科技发展有限公司 一种奥沙西罗晶体及含有该晶体的组合物
HRP20181197T1 (hr) * 2013-10-29 2018-11-30 Biomarin Pharmaceutical Inc. Derivati n-(1-hidroksi-3-(pirolidinil)propan-2-il)pirolidin-3-karboksamida kao inhibitori glukozilceramid sintaze
PL3204352T3 (pl) * 2014-10-06 2020-12-14 Cortexyme, Inc. Inhibitory gingipainy lizynowej
US11130780B2 (en) * 2015-03-09 2021-09-28 Washington University Inhibitors of growth factor activation enzymes
WO2017083433A1 (en) * 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
DK3512846T3 (da) 2016-09-16 2024-11-11 Lighthouse Pharmaceuticals Inc Ketonhæmmere af lysin-gingipain
CN110944637A (zh) 2017-05-10 2020-03-31 库特克希米公司 氨基吡啶化合物及其制备方法和使用方法
EP4159211A4 (en) * 2021-07-15 2024-10-30 National Center for Global Health and Medicine ASSOCIATED WITH PHYSIOLOGICAL ACTIVITY SUCH AS ANTIVIRAL ACTIVITY

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
JPH0820597A (ja) 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
AU4250896A (en) 1994-12-22 1996-07-10 Biochem Pharma Inc. Heterocyclic keto arginine peptides as thrombin inhibitors
WO1996019483A1 (en) 1994-12-22 1996-06-27 Biochem Pharma Inc. Low molecular weight bicyclic thrombin inhibitors
JPH10508035A (ja) 1995-03-24 1998-08-04 モレキュメティックス リミテッド βシート模倣物およびプロテアーゼインヒビターとしてのその使用
WO1996030396A1 (en) 1995-03-24 1996-10-03 Molecumetics Ltd. β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS
GB9510264D0 (en) 1995-05-22 1995-07-19 Iaf Biochem Int Low molecular weight bicyclic-urea type thrombin inhibitors
US5523308A (en) 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827866A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827860A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6069130A (en) * 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
AU732174B2 (en) 1996-08-05 2001-04-12 Myriad Genetics, Inc. Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
AU4172397A (en) 1996-09-06 1998-03-26 Biochem Pharma Inc. Lactam inhibitors of thrombin
US5827886A (en) * 1997-05-07 1998-10-27 Thione International, Inc. Composition for relief of arthritis-induced symptoms
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
AU1176299A (en) 1997-11-26 1999-06-15 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitors comprising heterocyclic amide compounds
KR100601810B1 (ko) 1997-12-16 2006-07-19 죤슨 앤드 죤슨 컨써머 캄파니스 인코포레이티드 식작용 및 ｉｃａｍ-1 발현을 조절하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
BG105762A (en) 2002-03-29
AR022427A1 (es) 2002-09-04
US20030008829A1 (en) 2003-01-09
EP1147097A1 (en) 2001-10-24
TR200102766T2 (tr) 2001-12-21
EE200100391A (et) 2002-10-15
CN1353701A (zh) 2002-06-12
HUP0201295A2 (en) 2002-09-28
WO2000044733A1 (en) 2000-08-03
HRP20010601A2 (en) 2002-08-31
BR0007778A (pt) 2002-06-04
YU61401A (sh) 2005-07-19
US6469036B1 (en) 2002-10-22
TWI229669B (en) 2005-03-21
NO20013666D0 (no) 2001-07-26
HUP0201295A3 (en) 2002-10-28
US7132418B2 (en) 2006-11-07
KR20010110422A (ko) 2001-12-13
NO20013666L (no) 2001-09-26
EA200100815A1 (ru) 2002-08-29
HK1038561A1 (zh) 2002-03-22
ZA200106995B (en) 2002-11-25
JP2002535394A (ja) 2002-10-22
AU3208500A (en) 2000-08-18
CA2361479A1 (en) 2000-08-03
SK10742001A3 (sk) 2002-08-06
CZ20012722A3 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
HUP0201295A2 (en) Peptidyl heterocyclic ketones useful as tryptase inhibitors
AU5741301A (en) Arylmethylamine derivatives for use as tryptase inhibitors
GB9900416D0 (en) Inhibitors
IL146518A0 (en) Metalloprotease inhibitors
PL350926A1 (en) Amine derivatives as protease inhibitors
GB9917909D0 (en) Cysteine protease inhibitors
PL350452A1 (en) Dihetero-substituted metalloprotease inhibitors
HUP0203855A3 (en) Substituted piperazine derivatives as mtp inhibitors
EP1153022A4 (en) PROTEASE INHIBITORS
GB9924522D0 (en) Enzyme inhibitors
EP1232155A4 (en) PROTEASE INHIBITORS
EP1229914A4 (en) PROTEASE INHIBITORS
EP1229915A4 (en) PROTEASE INHIBITORS
EP1231921A4 (en) PROTEASE INHIBITORS
EP1229912A4 (en) PROTEASE INHIBITORS
AU7545200A (en) Aminomethyl-(hetero)aryl derivatives and their use as tryptase inhibitors
EP1229911A4 (en) PROTEASE INHIBITORS
EP1173429A4 (en) PROTEASE INHIBITORS
EP1161237A4 (en) PROTEASE INHIBITORS
EP1233771A4 (en) PROTEASE INHIBITORS
EP1351930A4 (en) PROTEASE INHIBITORS
EP1231923A4 (en) PROTEASE INHIBITORS
IL150862A0 (en) Heterocyclic amide derivatives
GB9929037D0 (en) Heterocyclic derivatives
EP1232154A4 (en) PROTEASE INHIBITORS